Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 14 of 27
A Study Of Galcanezumab In Participants With Episodic Cluster Headache
NCT02397473
A Study of LY3022855 In Participants With Breast or Prostate Cancer
NCT02265536
A Study of Galunisertib on the Immune System in Participants With Cancer
NCT02304419
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
NCT02407054
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
NCT02308020
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
NCT02387801
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
NCT02439320
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
NCT02402933
A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
NCT02387814
A Study of LY2409021 Formulations in Healthy Participants
NCT02385084
A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children
NCT02370485
A Study of LY3154207 in Healthy Participants
NCT02365571
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
NCT02326025
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
NCT02314117
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
NCT02423343
A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants
NCT02365558
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
NCT02337387
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
NCT02349295
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
NCT02302716
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
NCT02323334
A Study of LY2623091 in Healthy Participants
NCT02300259
A Study of LY2835219 in Healthy Participants
NCT02256267
A Study of LY3079514 in Healthy Participants
NCT02242903
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
NCT02227784
A Study of How the Body Breaks Down and Eliminates LY2623091
NCT02242981
A Study of LY2409021 in Healthy Participants
NCT02217618
A Study of LY3164530 in Participants With Cancer
NCT02221882
A Study of LY2623091 in Participants With High Blood Pressure
NCT02194465
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
NCT02163993
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
NCT02197520
A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain
NCT02192190
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
NCT02124148
Safety Study of LY3041658 in Healthy Participants
NCT02148627
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
NCT02102490
Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
NCT02161731
A Study of LY2951742 in Healthy Japanese and Caucasian Participants
NCT02104765
A Study of LY3050258 in Healthy Participants
NCT02121834
A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis
NCT02144285
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
NCT02171130
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
NCT02152371
A Study of Evacetrapib in Participants With Abnormal Cholesterol
NCT02168803
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
NCT02132637
A Study of LY2835219 in Participants With Cancer
NCT02117648
A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
NCT02109042
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
NCT02111096
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
NCT02079636
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
NCT02082210
A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus
NCT02091362
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
NCT02008357
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
NCT01824290
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.